Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PARP1 | P09874 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TNKS | O95271 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967198 | 1.00 | TNKS2 (0.70) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL7526687 | 0.86 | PDE10A (0.69) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL16404338 | 0.85 | PDE10A (0.84) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL7410488 | 0.82 | PARP1 (0.71) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL3985227 | 0.82 | TNKS2 (0.70) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL30552887 | 0.82 | TNKS2 (0.70) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL2178119 | 0.82 | TNKS2 (0.70) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL19673854 | 0.82 | TNKS2 (0.70) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL30176850 | 0.82 | TNKS2 (1.00) | TNKS2KMT2APDE10AKDM4ELMNA | |
| SCHEMBL31716684 | 0.82 | TNKS2 (0.70) | TNKS2KMT2APDE10AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORP (US) | 2026-01-15 | — | — | US | disclosed |
| US-20240336591-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | Benevolentai Cambridge Limited (GB) | 2024-10-10 | — | — | US | disclosed |
| CN-118159530-A | Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling | 康福治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4377305-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | BenevolentAI Cambridge Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024112611-A1 | TARGETED PROTEIN MODIFICATION | WEATHERWAX BIOTECHNOLOGIES CORPORATION (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-115260164-B | Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117751107-A | Organic pyridine-pyrazole compounds and uses thereof | 博善人工智能剑桥有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4308183-A1 | BIOENGINEERED ENDOTHELIAL CONSTRUCTS | The University Of Sydney (AU) | 2024-01-24 | — | — | EP | disclosed |
| CN-117024357-A | Selective inhibitor for BRCA mutation and application thereof | 潍坊医学院 | 2023-11-10 | — | — | CN | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
| WO-2006074187-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-0801329-B1 | RADIATION-SENSITIVE COMPOSITION AND RECORDING MEDIUM PRODUCED THEREFROM | CLARIANT FINANCE BVI LTD (VG) | 2002-03-27 | — | — | EP | disclosed |
| US-6110639-A | Radiation-sensitive composition and recording medium using the same | HOECHST JAPAN LIMITED (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0801329-A1 | RADIATION-SENSITIVE COMPOSITION AND RECORDING MEDIUM PRODUCED THEREFROM | HOECHST JAPAN LIMITED (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | TNKS2 357/4885KMT2A 2316/4885PDE10A 1255/4885 |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | TNKS2 795/4885KMT2A 2811/4885PDE10A 3839/4885 |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA3, GABRA5, GABRA1 | TNKS2 4775/4885KMT2A 1120/4885PDE10A 1268/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | TNKS2 638/4885KMT2A 3878/4885PDE10A 3350/4885 |
| US-20240336591-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | ALPI, NOD1, PNPO | TNKS2 1265/4885KMT2A 4576/4885PDE10A 963/4885 |
| US-20260014261-A1 | TARGETED PROTEIN MODIFICATION | MDM2, TP53, VHL | TNKS2 1515/4885KMT2A 1128/4885PDE10A 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.